Posts by Mourabit Halima

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting took place from September 13 to 17 in Barcelona, Spain. At the event, Dr. Liangyou Gu from the Urology Department of Chinese PLA General Hospital shared findings from the Phase II NEOTAX study on neoadjuvant therapy for renal cancer patients with venous tumor thrombus. The study demonstrated that preoperative treatment with toripalimab combined with axitinib successfully downgraded the level of inferior vena cava (IVC) tumor thrombus in some patients, significantly improving perioperative outcomes. Urology Frontier had the privilege of interviewing Dr. Liangyou Gu at the event for an in-depth analysis of the NEOTAX study, treatment strategies for renal cancer with venous tumor thrombus, and future research directions.

As antibody-drug conjugates (ADCs) and precision medicine continue to develop, breast cancer is entering a new era of treatment. At the 2024 CSCO Annual Conference, Dr. Jian Zhang from Fudan University Shanghai Cancer Center and Dr. Nadia Harbeck from LMU University Hospital, Munich,Germany engaged in a deep discussion about the latest developments in breast cancer treatment. The two professors shared insights into the remarkable efficacy and safety management strategies of ADC drugs in treating HR+ advanced breast cancer patients, while also exploring the critical role of genetic testing in guiding individualized treatment. This dialogue not only reveals the global cutting-edge trends in breast cancer treatment but also provides valuable guidance for future clinical practice, leading the field towards more precise and individualized treatment approaches.

The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain. As one of the largest and most prestigious clinical oncology conferences in the world, it showcased numerous cutting-edge research findings, driving global advancements in oncology. In the field of breast cancer, Dr. Xiaojia Wang from Zhejiang Cancer Hospital presented a study on first-line treatment for advanced triple-negative breast cancer (TNBC) using a combination of two immunotherapy drugs and chemotherapy. The study, conducted alongside Professor Quchang Ouyang from Hunan Cancer Hospital, highlighted the promising outcomes of combining ivonescimab, a dual PD-1/VEGF inhibitor, with chemotherapy. This research was selected for oral presentation (#347MO) at the ESMO Congress, showcasing the innovation and research achievements of Chinese scientists.

At the 2024 European Society for Medical Oncology (ESMO) Congress, Dr. Myriam Chalabi from Amsterdam, Netherlands, unveiled the latest results from the NICHE-2 study, showing a groundbreaking three-year disease-free survival (DFS) rate of 100% in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer undergoing neoadjuvant immunotherapy. This large-scale study provides critical evidence supporting neoadjuvant immunotherapy, overcoming the limitations of the NICHE-1 study, which had a smaller sample size. In this article, we summarize the key findings of NICHE-2 and discuss the latest results from NICHE-3, presenting the latest advancements in this field.

The release of studies like HIMALAYA has marked the beginning of the dual immunotherapy era in advanced liver cancer treatment. As the majority of Chinese liver cancer patients are diagnosed at an advanced stage, finding the optimal systemic therapy, including durvalumab, in combination with local therapies to further improve patient outcomes has become a research focus. At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, held from September 13 to 17 in Barcelona, Spain, Dr. Rongping Guo's team from Sun Yat-sen University Cancer Center presented the results of their HILL study (982P) in a poster session. The study demonstrated that the combination of durvalumab, lenvatinib, and hepatic arterial infusion chemotherapy (HAIC) achieved a 2-year overall survival (OS) rate of 94%, with manageable side effects, contributing valuable insights from China for the treatment of advanced liver cancer. Oncology Frontier invited Dr. Rongping Guo for an in-depth interview to discuss the study.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13-17 in Barcelona, Spain. As one of the largest and most prestigious global clinical oncology conferences, it showcased groundbreaking research from experts around the world, advancing the field of oncology. In the hematologic malignancy space, this year's ESMO also featured many key advancements, including research from China. One such study, led by Dr. Hongyan Tong from The First Affiliated Hospital of Zhejiang University Medical College, was selected for an oral presentation. The study explored the efficacy of Timdarpacept (IMM01) combined with azacitidine (AZA) as a first-line treatment for chronic myelomonocytic leukemia (CMML) (801 MO). Hematology Frontier had the opportunity to interview Dr. Maria Ma, one of the team members, who provided an in-depth explanation of the study.

The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting will be held from September 13-17 in Barcelona, Spain. At this upcoming ESMO 2024 conference, Dr. Fei Ma from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College will present two Mini Oral reports (344MO, 349MO) on the novel Trop-2 antibody-drug conjugate (ADC) ESG401. These two studies not only highlight the significant efficacy of ESG401 in HER2-negative breast cancer with brain metastases but also reveal its broad potential application across different subtypes of metastatic breast cancer. This provides new treatment options for breast cancer patients and opens new directions for the research and development of Trop-2 ADC drugs. Oncology Frontier invited Dr. Fei Ma to introduce the key aspects of these two studies, and we look forward to his exciting presentation at ESMO 2024, contributing Chinese insights and expertise to global breast cancer treatment.

At the 2024 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Hitomi Sakai from the Advanced Cancer Translational Research Institute in Japan reported on the significant efficacy of the OLZ-based triple therapy in preventing treatment-related nausea and vomiting (NV) in patients treated with T-DXd, providing an important reference for clinical practice. After the conference, Dr. Hitomi Sakai was interviewed by Oncology Frontier, where she introduced the research process and related results.